Beijing SL Pharmaceutical Lamivudine Receives Approval
This article was originally published in PharmAsia News
Beijing SL Pharmaceutical has received a production license and new drug certification for its lamivudine capsule and lamivudine raw material for treating the hepatitis B virus. At present, TIPR Pharmaceutical's Daiding ranks top in China's lamivudine market with 57.75 percent, and GSK's Heptodin accounting for the remaining market share. According to estimates, hospitals in the country spend RMB 480 million on lamivudine and the drug will hit RMB 1 billion in revenue by 2010. Beijing SL believes that few companies have the capability to produce the drug, and supply still lags behind demand. It is thus optimistic about the potential of the product and will go into production soon. (Click here for more - Chinese Language)
You may also be interested in...
Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.
Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.
Results of Study to Assess Statin Residual Risk with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridemia “should prompt reconsideration of [OTC] mixed omega-3 fatty acid products for [atherosclerotic cardiovascular disease] prevention,” say cardiologists in an editorial published with JAMA study.